Page last updated: 2024-10-31

mitotane and Hypogonadism

mitotane has been researched along with Hypogonadism in 2 studies

Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.

Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).

Research Excerpts

ExcerptRelevanceReference
"Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied."8.31Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023)
"Mitotane is a drug which is concentrated largely in adipose tissue and the adrenal glands."5.27Primary hypogonadism associated with o,p' DDD (mitotane) therapy. ( Sparagana, M, 1987)
"Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied."4.31Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023)
"Mitotane is a drug which is concentrated largely in adipose tissue and the adrenal glands."1.27Primary hypogonadism associated with o,p' DDD (mitotane) therapy. ( Sparagana, M, 1987)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Delbarba, A1
Cosentini, D1
Facondo, P1
Laganà, M1
Pezzaioli, LC1
Cremaschi, V1
Alberti, A1
Grisanti, S1
Cappelli, C1
Ferlin, A1
Berruti, A1
Sparagana, M1

Other Studies

2 other studies available for mitotane and Hypogonadism

ArticleYear
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Humans; Hypogonadism; Longitudinal St

2023
Primary hypogonadism associated with o,p' DDD (mitotane) therapy.
    Journal of toxicology. Clinical toxicology, 1987, Volume: 25, Issue:6

    Topics: ACTH Syndrome, Ectopic; Adult; Erectile Dysfunction; Gonadotropins; Humans; Hypogonadism; Luteinizin

1987